DK0886527T3 - Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon - Google Patents
Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferonInfo
- Publication number
- DK0886527T3 DK0886527T3 DK97905395T DK97905395T DK0886527T3 DK 0886527 T3 DK0886527 T3 DK 0886527T3 DK 97905395 T DK97905395 T DK 97905395T DK 97905395 T DK97905395 T DK 97905395T DK 0886527 T3 DK0886527 T3 DK 0886527T3
- Authority
- DK
- Denmark
- Prior art keywords
- natural human
- human alpha
- pharmaceutical compositions
- compositions containing
- containing natural
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM960136 IT1283945B1 (it) | 1996-02-28 | 1996-02-28 | Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da |
IT96RM000427 IT1284852B1 (it) | 1996-06-14 | 1996-06-14 | Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da |
PCT/IT1997/000040 WO1997031649A1 (en) | 1996-02-28 | 1997-02-27 | PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN α-INTERFERON |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0886527T3 true DK0886527T3 (da) | 2002-03-04 |
Family
ID=26332096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97905395T DK0886527T3 (da) | 1996-02-28 | 1997-02-27 | Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon |
Country Status (14)
Country | Link |
---|---|
US (1) | US6884411B1 (ko) |
EP (1) | EP0886527B1 (ko) |
JP (1) | JP2000506839A (ko) |
KR (1) | KR100394382B1 (ko) |
AT (1) | ATE205397T1 (ko) |
AU (1) | AU722987B2 (ko) |
BR (1) | BR9707772A (ko) |
DE (1) | DE69706657T2 (ko) |
DK (1) | DK0886527T3 (ko) |
EA (1) | EA001147B1 (ko) |
ES (1) | ES2160927T3 (ko) |
GE (1) | GEP20012489B (ko) |
PT (1) | PT886527E (ko) |
WO (1) | WO1997031649A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
ITMI20030826A1 (it) * | 2003-04-18 | 2004-10-19 | Unihart Corp | Composizione farmaceutica contenente interferone per il |
ES2303492A1 (es) * | 2004-08-18 | 2008-08-01 | Instituto Cientifico Y Tecnologico De Navarra S.A. | Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden. |
WO2006032711A1 (es) * | 2004-08-18 | 2006-03-30 | Instituto Científico Y Tecnológico De Navarra S.A. | Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA878295B (en) * | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
CA1320905C (en) * | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
TW224053B (ko) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US5980884A (en) * | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
HUP9602024A3 (en) * | 1996-07-25 | 1999-05-28 | Toth Sandor | Pharmaceutical composition containing aminoacid for external use |
-
1997
- 1997-02-27 AT AT97905395T patent/ATE205397T1/de not_active IP Right Cessation
- 1997-02-27 EA EA199800770A patent/EA001147B1/ru not_active IP Right Cessation
- 1997-02-27 DE DE69706657T patent/DE69706657T2/de not_active Expired - Fee Related
- 1997-02-27 BR BR9707772-0A patent/BR9707772A/pt not_active Application Discontinuation
- 1997-02-27 ES ES97905395T patent/ES2160927T3/es not_active Expired - Lifetime
- 1997-02-27 EP EP97905395A patent/EP0886527B1/en not_active Expired - Lifetime
- 1997-02-27 US US09/125,122 patent/US6884411B1/en not_active Expired - Fee Related
- 1997-02-27 KR KR10-1998-0706297A patent/KR100394382B1/ko not_active IP Right Cessation
- 1997-02-27 AU AU22299/97A patent/AU722987B2/en not_active Ceased
- 1997-02-27 DK DK97905395T patent/DK0886527T3/da active
- 1997-02-27 PT PT97905395T patent/PT886527E/pt unknown
- 1997-02-27 JP JP9530771A patent/JP2000506839A/ja not_active Ceased
- 1997-02-27 WO PCT/IT1997/000040 patent/WO1997031649A1/en not_active Application Discontinuation
- 1997-02-27 GE GEAP19974506A patent/GEP20012489B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR100394382B1 (ko) | 2004-02-05 |
GEP20012489B (en) | 2001-07-25 |
EP0886527B1 (en) | 2001-09-12 |
EP0886527A1 (en) | 1998-12-30 |
US6884411B1 (en) | 2005-04-26 |
JP2000506839A (ja) | 2000-06-06 |
DE69706657T2 (de) | 2002-06-20 |
ES2160927T3 (es) | 2001-11-16 |
AU2229997A (en) | 1997-09-16 |
AU722987B2 (en) | 2000-08-17 |
EA199800770A1 (ru) | 1999-02-25 |
KR19990082559A (ko) | 1999-11-25 |
ATE205397T1 (de) | 2001-09-15 |
DE69706657D1 (de) | 2001-10-18 |
WO1997031649A1 (en) | 1997-09-04 |
BR9707772A (pt) | 2000-01-04 |
EA001147B1 (ru) | 2000-10-30 |
PT886527E (pt) | 2001-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR012614A1 (es) | Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento | |
DK0911033T3 (da) | Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis | |
HUP0103423A2 (hu) | Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében | |
DK0871748T3 (da) | Indgivelse af biologisk aktive polypeptider | |
ATE165000T1 (de) | Dosierungsform zur verzoegerten wirkstofffreisetzung | |
HUP0101293A2 (hu) | AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása | |
ITRM910922A1 (it) | Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico | |
HUP0100092A2 (hu) | Kombinációs terápia kimutatható HCV-RNS eradikációjára krónikus hepatitis-C fertőzött betegekben | |
MX171191B (es) | Composiciones farmaceuticas de glipizida | |
GEP19981482B (en) | Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B | |
DK486588A (da) | Konjungater af cytokininer med immunglobuliner | |
DK0527835T3 (da) | Doseringsform til afgivelse af et anti-Parkinsonmiddel | |
HUP0102033A2 (hu) | PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére | |
EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
RU92016463A (ru) | Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе | |
HK1030157A1 (en) | Use of consensus interferon and compositions comprising consensus interferon. | |
DK0886527T3 (da) | Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon | |
BR0108997A (pt) | Terapia imune adjuvante para hiv | |
HK1041215A1 (en) | Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection. | |
ES2089286T3 (es) | Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos. | |
AU2880595A (en) | Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses | |
KR950702838A (ko) | 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4) | |
OA08768A (fr) | Traitement du virus su SIDA par l'interféron alpha humain recombinant. | |
HUP9902188A2 (hu) | Természetes humán alfa-interferont tartalmazó gyógyszerkészítmények | |
IT1284852B1 (it) | Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da |